Cargando…
Efficacy, Safety, and Subject Satisfaction of PrabotulinumtoxinA for Moderate-to-Severe Crow’s Feet: A Phase IV, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
PrabotulinumtoxinA has been identified as an effective agent against crow’s feet. Our study, which included Korean patients with moderate to severe crow’s feet, was undertaken to compare the efficacy and safety of PrabotulinumtoxinA and placebo treatments. Of the 90 study participants, 60 received p...
Autores principales: | Lee, Soo-Kyung, Kim, Myoung Shin, Kwon, Soon-Hyo, Chung, Bo Young, Han, Se Hee, Kim, Hyoung Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573474/ https://www.ncbi.nlm.nih.gov/pubmed/37834970 http://dx.doi.org/10.3390/jcm12196326 |
Ejemplares similares
-
A Preclinical Study Comparing the Activity and Potency of OnabotulinumtoxinA and PrabotulinumtoxinA
por: Rupp, David C, et al.
Publicado: (2023) -
PrabotulinumtoxinA for Treatment of Millennials With Moderate to Severe Glabellar Lines: Post Hoc Analyses of the Phase III Clinical Study Data
por: Ogilvie, Patricia, et al.
Publicado: (2022) -
Safety and Efficacy of PrabotulinumtoxinA (Nabota(®)) Injection for Cervical and Shoulder Girdle Myofascial Pain Syndrome: A Pilot Study
por: Kim, Da-ye, et al.
Publicado: (2018) -
The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients
por: Lorenc, Z Paul, et al.
Publicado: (2021) -
The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II
Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar
Lines in Adult Patients
por: Kaufman-Janette, Joely, et al.
Publicado: (2021)